NCT07094022

Improvement and Safety of Nutrilite Protein MetX Pro on Weight Management in Overweight Individuals With Dyslipidemia

A Randomized, Double-blind, Placebo-controlled, Single Center Study to Evaluate of the Improvement and Safety of Nutrilite Protein MetX Pro on Weight Management in Overweight Individuals With Dyslipidemia

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: Amway (China) R&D Center · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The goal of this randomized, double-blind, placebo-controlled, single center study is to evaluate the impact of Nutrilite Protein MetX Pro (the study product, a high-protein compound beverages supplemented with multiple plant proteins and apple extracts) on lipid profiles in the blood test in overweight individuals with dyslipidemia. The main question it aims to answer is: \- Does the intake of the study product improve the blood lipid profiles (TC,TG, LDL-C ) in terms of of overweight individuals with dyslipidemia? Researchers will compare the product group to a placebo group to see whether the blood lipid profile is significantly better improved for participants in the product group. Participants will: * take randomly assigned products 16g/each time, twice a day for 4 weeks * make four times site visits, once a week. Blood samples are collected for each visit, and Feces are collected for the first and last site visit.

Conditions

• Dyslipidemia
• Obesity &Amp; Overweight

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Nutrilite Protein MetX Pro	A total of 4 cans (460 g/can) of study products (Nutrilite Protein MetX Pro) are distributed to each participant. Participants need to take 16g each time, twice a day, for 4 weeks.
DIETARY_SUPPLEMENT	Placebo Product	A total of 4 cans (460 g/can) of placebo products are distributed to each participant. Participants need to take 16g each time, twice a day, for 4 weeks.

Timeline

• Start date: 2025-03-16
• Primary completion: 2025-06-03
• Completion: 2025-06-03
• First posted: 2025-07-30
• Last updated: 2025-07-30

Locations

2 sites across 1 country: China